A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome

European Radiology

Volumn 27, Issue 9, 2017, Pages 3991-4001

  Vargas, Hebert Alberto ^a   Veeraraghavan, Harini ^a   Micco, Maura ^a   Nougaret, Stephanie ^a,b,c   Lakhman, Yulia ^a   Meier, Andreas A ^a   Sosa, Ramon ^a   Soslow, Robert A ^a   Levine, Douglas A ^a   Weigelt, Britta ^a   Aghajanian, Carol ^a   Hricak, Hedvig ^a   Deasy, Joseph ^a   Snyder, Alexandra ^a   Sala, Evis ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Ovarian cancer; Radiogenomics; Radiomics; Survival; Texture

Indexed keywords

CYCLIN E; CYCLIN E1; UNCLASSIFIED DRUG; CCNE1 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER SURVIVAL; CHROMOSOME 19Q; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DECISION TREE; ENTROPY; FEMALE; GENE AMPLIFICATION; GYNECOLOGIC SURGERY; HUMAN; IMAGE ANALYSIS; NON INVASIVE MEASUREMENT; NORMAL DISTRIBUTION; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TRANSCRIPTOMICS; ADULT; AGED; EVALUATION STUDY; GENETICS; MIDDLE AGED; MORTALITY; NUCLEIC ACID AMPLIFICATION; OVARY TUMOR; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; CYCLIN E; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85015108153     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-017-4779-y     Document Type: Article

References (25)

1. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J et al (2002) Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 38:2435–2445
2. Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF et al (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703–3709
3. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–5208
4. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ et al (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123:517–525
5. Soslow RA (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27:161–174
6. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA (2007) Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 211:286–295
7. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB et al (2012) Radiomics: the process and the challenges. Magn Reson Imaging 30:1234–1248
8. Haralick RM, Shanmugam K, Dinstein IH (1973) Textural features for image classification. IEEE Trans Syst Man Cyber SMC-3:610–621
9. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006
10. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680
11. Vargas HA, Micco M, Hong SI, Goldman DA, Dao F, Weigelt B et al (2015) Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology 274:742–751
12. Veeraraghavan H, Schrater P, Papanikolopoulos NP (2006) Adaptive templates for feature matching. Proc IEEE Int Conf Robot Autom 3393–3398
13. Tibshirani R (1996) Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol 58:267–288
14. Ture MTF, Kurt I (2009) Using Kaplan-Meier analysis together with decision tree methods in determining recurrence-free survival of breast cancer patients. Expert Syst Appl 36:2017–2026
15. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G et al (2009) Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res Off J Am Assoc Cancer Res 15:1417–1427
16. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S et al (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521:489–494
17. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892
18. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H et al (2015) Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518:240–244
19. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240–2247
20. Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM et al (2015) Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med 12:e1001789
21. Mittempergher L (2016) Genomic characterization of high-grade serous ovarian cancer: dissecting its molecular heterogeneity as a road towards effective therapeutic strategies. Curr Oncol Rep 18:44
22. Paracchini L, Mannarino L, Craparotta I, Romualdi C, Fruscio R, Grassi T et al (2016) Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies. Oncotarget. doi:10.18632/oncotarget.10505
23. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY) 348:124–128
24. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 387:1909–1920
25. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44